Sanuwave Health (NASDAQ:SNWV – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.17), FiscalAI reports. Sanuwave Health had a net margin of 6.22% and a return on equity of 123.57%. The company had revenue of $8.58 million during the quarter, compared to analysts’ expectations of $13.75 million.
Sanuwave Health Trading Down 5.3%
NASDAQ:SNWV opened at $1.78 on Thursday. Sanuwave Health has a 52 week low of $1.58 and a 52 week high of $35.72. The firm has a 50-day moving average price of $4.62 and a two-hundred day moving average price of $12.65. The company has a debt-to-equity ratio of 4.87, a quick ratio of 0.89 and a current ratio of 1.28. The firm has a market cap of $15.31 million, a price-to-earnings ratio of -4.68 and a beta of 1.47.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded shares of Sanuwave Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, November 4th. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $47.00.
View Our Latest Report on Sanuwave Health
Sanuwave Health Company Profile
SANUWAVE Health, Inc. is a medical technology company focused on regenerative medicine and advanced wound-care solutions. The company develops and commercializes noninvasive devices that use extracorporeal shock wave technology to stimulate biological responses in damaged or difficult-to-heal tissue. Its principal product is the dermaPACE system, which is designed to deliver acoustic shock waves to wound areas, including chronic diabetic foot ulcers. SANUWAVE has also pursued additional applications for its platform in areas such as orthopedic and soft-tissue healing, although the availability and regulatory status of specific products may vary by geography.
Featured Stories
- Five stocks we like better than Sanuwave Health
- The Post-Midterm Rally Clock Is Ticking—and These 3 AI Stocks Stand Out
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
Receive News & Ratings for Sanuwave Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanuwave Health and related companies with MarketBeat.com's FREE daily email newsletter.
